

Application No: 09/522,753

Attorney Docket No: SALK 1510-3

Filing Date: March 10, 2000

(088802-8704)

Response to Office Action (mailed April 20, 2004) faxed August 20, 2004

Page 2 of 13

### LISTING OF CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1.- 2. (Cancelled)
3. (Previously presented) The polynucleotide of claim 4, wherein the SMRT co-repressor comprises a repression domain having
  - a) less than about 83% identity with a Sin3A interaction domain of N-CoR set forth as amino acids 255 to 312 of SEQ ID NO: 11;
  - b) less than about 57% identity with repression domain 1 of N-CoR set forth as amino acids 1 to 312 of SEQ ID NO: 11;
  - c) less than about 66% identity with a SANT domain of N-CoR set forth as amino acids 312 to 668 of SEQ ID NO: 11; or
  - d) less than about 30% identity with repression domain 2 of N-CoR set forth as amino acids 736 to 1031 of SEQ ID NO: 11.
4. (Previously presented) An isolated polynucleotide encoding a SMRT co-repressor (silencing mediator of retinoic acid receptor and thyroid hormone receptor), or a peptide portion thereof, or an isolated polynucleotide complementary thereto, wherein said SMRT co-repressor or peptide portion thereof is capable of mediating the transcriptional silencing of at least one member of the steroid/thyroid hormone superfamily of receptors, and wherein the SMRT co-repressor or peptide portion thereof comprises an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 5.

Application No: 09/522,753

Attorney Docket No: SALK 1510-3

Filing Date: March 10, 2000

(088802-8704)

Response to Office Action (mailed April 20, 2004) faxed August 20, 2004

Page 3 of 13

5. (Previously presented) An isolated polynucleotide encoding a SMRT co-repressor (silencing mediator of retinoic acid receptor and thyroid hormone receptor), or a peptide portion thereof, or an isolated polynucleotide complementary thereto, wherein said SMRT co-repressor or peptide portion thereof is capable of mediating the transcriptional silencing of at least one member of the steroid/thyroid hormone superfamily of receptors, and wherein said SMRT co-repressor or peptide portion thereof is encoded by a polynucleotide having at least 80% sequence identity with SEQ ID NO: 4.

6.- 8. (Cancelled)

9. (Previously presented) An isolated polynucleotide encoding a SMRT co-repressor (silencing mediator of retinoic acid receptor and thyroid hormone receptor), or a peptide portion thereof, or an isolated polynucleotide complementary thereto, wherein said SMRT co-repressor or peptide portion thereof is capable of mediating the transcriptional silencing of at least one member of the steroid/thyroid hormone superfamily of receptors, wherein said polynucleotide encodes said SMRT co-repressor or peptide portion thereof, and wherein said SMRT co-repressor or peptide portion thereof has at least 80% sequence identity with SEQ ID NO: 7.

10. (Previously presented) The polynucleotide of claim 9, which has a nucleotide sequence having at least 80% sequence identity with SEQ ID NO: 6.

11. (Cancelled)

Application No: 09/522,753

Attorney Docket No: SALK 1510-3

Filing Date: March 10, 2000

(088802-8704)

Response to Office Action (mailed April 20, 2004) faxed August 20, 2004

Page 4 of 13

12. (Previously presented) An isolated polynucleotide encoding a SMRT co-repressor (silencing mediator of retinoic acid receptor and thyroid hormone receptor), or a peptide portion thereof, or an isolated polynucleotide complementary thereto, wherein said SMRT co-repressor or peptide portion thereof is capable of mediating the transcriptional silencing of at least one member of the steroid/thyroid hormone superfamily of receptors, wherein said polynucleotide encodes said SMRT co-repressor or peptide portion thereof, and wherein said SMRT co-repressor or peptide portion thereof has at least 80% sequence identity with SEQ ID NO: 9.

13. (Previously presented) The polynucleotide of claim 12, which has a nucleotide sequence having at least 80% sequence identity with SEQ ID NO: 8.

14. (Previously presented) A first isolated polynucleotide encoding a SMRT co-repressor (silencing mediator of retinoic acid receptor and thyroid hormone receptor), or a peptide portion thereof, or a second isolated polynucleotide complementary thereto, wherein said SMRT co-repressor or peptide portion thereof is capable of mediating the transcriptional silencing of at least one member of the steroid/thyroid hormone superfamily of receptors, and wherein said first polynucleotide is selected from the group consisting of:

(a) a nucleotide sequence having at least 80% sequence identity with nucleotides 1 to 3094 of SEQ ID NO: 4;

(b) a nucleotide sequence having at least 80% sequence identity with nucleotides 1 to 3718 of SEQ ID NO: 6;

(c) a nucleotide sequence having at least 80% sequence identity with nucleotides 1 to 2801 of SEQ ID NO: 8; and

(d) polynucleotides complementary to the sequence of (a), (b), or (c),  
provided that the polynucleotide does not contain a sequence identical to SEQ ID NO: 11.

15. (Cancelled)

Application No: 09/522,753

Attorney Docket No: SALK 1510-3

Filing Date: March 10, 2000

(088802-8704)

Response to Office Action (mailed April 20, 2004) faxed August 20, 2004

Page 5 of 13

16. (Previously presented) A first polynucleotide according to claim 14, wherein said first polynucleotide is selected from the group consisting of:

- (a) nucleotides 1 to 3094 of SEQ ID NO: 4;
- (b) nucleotides 1 to 3718 of SEQ ID NO: 6;
- (c) nucleotides 1 to 2801 of SEQ ID NO: 8; and
- (d) polynucleotides having at least 80% sequence identity with the complementary sequence of (a), (b), or (c).

17. (Previously presented) The polynucleotide of claim 10, comprising nucleotides 1 to 8388 of SEQ ID NO: 6.

18. (Previously presented) The polynucleotide of claim 5, comprising nucleotides 1 to 8561 of SEQ ID NO: 4.

19. (Previously presented) The polynucleotide of claim 4, which is operably linked to a second nucleotide sequence.

20. (Previously presented) The polynucleotide of claim 19, which encodes a fusion polypeptide comprising the SMRT co-repressor operably linked to a DNA binding domain of a transcription factor.

21. (Previously presented) A vector comprising the polynucleotide of claim 4.

22. (Previously presented) A host cell containing the polynucleotide of claim 4.

Application No: 09/522,753

Attorney Docket No: SALK 1510-3

Filing Date: March 10, 2000

(088802-8704)

Response to Office Action (mailed April 20, 2004) faxed August 20, 2004

Page 6 of 13

23. (Previously presented) An isolated oligonucleotide, comprising at least 15 nucleotides, that hybridizes, under suitable stringency conditions, to the polynucleotide of claim 4, but does not hybridize to a polynucleotide encoding SEQ ID NO: 11 or to a polynucleotide encoding an amino acid sequence consisting of amino acids 1031 to 2517 of SEQ ID NO: 5.

24. (Previously presented) The oligonucleotide of claim 23, wherein the polynucleotide encodes at least five contiguous amino acids of a sequence selected from the group consisting of:

amino acids 720 to 745 of SEQ ID NO: 5;

amino acids 716 to 742 of SEQ ID NO: 7; and

amino acids 497 to 523 of SEQ ID NO: 9.

25. (Previously presented) The oligonucleotide of claim 23, which hybridizes, under suitable stringency conditions, to a polynucleotide encoding SEQ ID NO: 5 or SEQ ID NO: 7, but does not hybridize to a polynucleotide encoding SEQ ID NO: 9.

26.- 37. (Cancelled)

38. (Previously presented) A polynucleotide of claim 13, wherein said polynucleotide comprises nucleotides 1 to 7465 of SEQ ID NO: 8.